Literature DB >> 29747858

Timing of Referral of Patients With Severe Isolated Tricuspid Valve Regurgitation to Surgeons (from a French Nationwide Database).

Julien Dreyfus1, Nicolas Ghalem2, Eric Garbarz2, Claire Cimadevilla3, Patrick Nataf3, Alec Vahanian2, Gilbert Caranhac4, David Messika-Zeitoun5.   

Abstract

Series evaluating the results of isolated tricuspid valve surgery (ITVS) are rare and often limited by small sample size, selection bias, and/or long period of enrollment. Based on a mandatory administrative national database, we collected all consecutive ITVS performed in France during a 2-year period (2013 and 2014), the type of intervention, clinical profile, and in-hospital mortality and complications. During the 2-year period, 241 patients underwent an ITVS in France (84 repairs and 157 replacements). In-hospital mortality was high (10%), and most patients experienced at least 1 complication (65%) with a 19% rate of major complications (death, need for dialysis, or need for mechanical support using extracorporeal membrane oxygenation). Consequently, hospital duration was remarkably long (26 ± 40 days). Congestive heart failure at presentation was associated with mortality and major complications rates (both p = 0.01). In conclusion, in a contemporary and consecutive series, ITVS was associated with a high mortality and morbidity predicted by clinical presentation at baseline. Our results suggest that patients are often referred too late and that an earlier intervention may improve immediate and possibly midterm outcomes. With the availability of transcatheter therapies in a near future, optimal timing of intervention in this population will be of utmost importance.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29747858     DOI: 10.1016/j.amjcard.2018.04.003

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Tricuspid Valve Percutaneous Therapies.

Authors:  Bhaskar Bhardwaj; Joaquin E Cigarroa; Firas Zahr
Journal:  Curr Cardiol Rep       Date:  2022-06-29       Impact factor: 3.955

Review 2.  Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field.

Authors:  Lluis Asmarats; Maurizio Taramasso; Josep Rodés-Cabau
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

3.  Surgical management of tricuspid regurgitation: a new algorithm to minimise recurrent tricuspid regurgitation.

Authors:  Diego Rodriguez Torres; Lucía Torres Quintero; Diego Segura Rodríguez; Jose Manuel Garrido Jimenez; Maria Esteban Molina; Francisco Gomera Martínez; Eduardo Moreno Escobar; Rocio Garcia Orta
Journal:  Open Heart       Date:  2022-07

Review 4.  Transcatheter and surgical treatment of tricuspid regurgitation: Predicting right ventricular decompensation and favorable responders.

Authors:  Alessandra Sala; Alessandro Beneduce; Francesco Maisano
Journal:  Front Cardiovasc Med       Date:  2022-09-27

5.  TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery.

Authors:  Julien Dreyfus; Etienne Audureau; Yohann Bohbot; Augustin Coisne; Yoan Lavie-Badie; Maxime Bouchery; Michele Flagiello; Baptiste Bazire; Florian Eggenspieler; Florence Viau; Elisabeth Riant; Yannick Mbaki; Damien Eyharts; Thomas Senage; Thomas Modine; Martin Nicol; Fabien Doguet; Virginia Nguyen; Thierry Le Tourneau; Christophe Tribouilloy; Erwan Donal; Jacques Tomasi; Gilbert Habib; Christine Selton-Suty; Richard Raffoul; Bernard Iung; Jean-François Obadia; David Messika-Zeitoun
Journal:  Eur Heart J       Date:  2022-02-12       Impact factor: 29.983

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.